Solbec granted patent
Thursday, 29 September, 2005
Solbec Pharmaceuticals (ASX:SBP) has been granted an Australian patent giving the company the monopoly right to prevent others from isolating the rhamnose binding protein receptor of its lead compound Coramsine.
Last month Solbec was granted a US patent based on the same inventive material. The RBP receptor is over-expressed in mammalian cancer cells, but not in healthy cells, and explains why Solbec's Coramsine is selective in targeting cancer cells.
The term of the patent runs until February 2023.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
